



14<sup>th</sup> November 2023

## **REMAP-CAP and RECOVERY collaboration plan for influenza treatments**

Given the overlap between the trials and the influenza treatments being tested, the chief investigators have decided that REMAP-CAP and RECOVERY will collaborate to maximise our chance of success. This collaboration involves:

- 1) **Co-ordination of recruitment locations**, so that only one trial is active in a particular clinical area. This will avoid confusion and unnecessary duplication of procedures, allowing more efficient recruitment. It will also allow site teams to choose the trial that will work best in their setting, which could include running different trials in different clinical locations in the same hospital where this is the most practical solution (e.g. ICUs and medical wards).
- 2) **A combined primary analysis and publication** including all patients recruited to either trial, which will maximise our chance of producing conclusive results.

### **What this means for sites**

- If you are already running REMAP-CAP or RECOVERY influenza comparisons at any locations in your trust, then please continue to do so.
- If you are in the process of setting up either trial at your site, please continue to do so.
- However, if there are clinical areas where you are not yet recruiting patients with influenza into either trial, we would like to invite you to participate in one of the trials.
- Both trials will now offer £400 per randomised participant to support trial sites with recruitment.

Note, all hospitalised patients are now potentially eligible for REMAP-CAP influenza comparisons, not just those on ICU. If your site is currently running REMAP-CAP on ICU alone, then please consider expanding REMAP-CAP to medical wards. If this is not possible, then please consider if it would be possible to run RECOVERY on medical wards.

### **What to do next if you are interested**

If you are interested in opening REMAP-CAP or RECOVERY influenza comparisons, or want to know more, then contact us at one of the addresses below:

REMAP-CAP – [ukremap-cap@icnarc.org](mailto:ukremap-cap@icnarc.org)

RECOVERY – [recoverytrial@ndph.ox.ac.uk](mailto:recoverytrial@ndph.ox.ac.uk)

If you are potentially interested in opening REMAP-CAP or RECOVERY influenza comparisons in any area in your trust, then please start local discussions now and contact us as soon as possible. We hope that by the two trials collaborating we will finally get answers about how best to manage influenza in hospital. We will hopefully also show that the UK and the NHS can lead the way in such clinical trials. Please join us.

Best wishes,

Anthony Gordon, Peter Horby and Martin Landray  
On behalf of the REMAP-CAP and RECOVERY teams

Paul Dark  
NIHR Deputy Medical Director